Top

Published in:

01-11-2018 | Editorial

Primary hyperparathyroidism in prostate cancer: guilty or not guilty?

Authors: G. Mazziotti, S. Frara, A. Mosca

Published in: Endocrine | Issue 2/2018

Excerpt

Skeletal health is a clinically relevant issue in patients with prostate cancer (PC) [1‐3]. Bone is the most common site of PC cell migration with up to 90% of patients with advanced disease having bone metastases [4] with potential negative impact on quality of life and survival [5]. Since the first description of the “seed and soil” hypothesis by Stephan Paget in 1889 [6], several cellular signaling pathways, cytokines, chemokines, and adhesion molecules have been identified as players of cross-talking between PC cells and bone [7] attempting to relate them either to metastases diagnosis or to patients’ prognosis (as prognostic factors) or to response to therapy (as predictive factors) [8]. …

R.A. Adler, Prostate cancer treated with androgen deprivation therapy has consequences for bone. Endocrine 45(3), 339–340 (2014). https://doi.org/10.1007/s12020-013-0113-x CrossRefPubMed

A.-C.M. Lassemillante, S.A.R. Doi, J.D. Hooper, J.B. Prins, O.R.L. Wright, Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45(3), 370–381 (2014). https://doi.org/10.1007/s12020-013-0083-z CrossRefPubMed

A.-C.M. Lassemillante, S.A.R. Doi, J.D. Hooper, J.B. Prins, O.R.L. Wright, Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine 50(2), 344–354 (2015). https://doi.org/10.1007/s12020-015-0536-7 CrossRefPubMed

L. Bubendorf, A. Schopfer, U. Wagner, G. Sauter, H. Moch, N. Willi, T.C. Gasser, M.J. Mihatsch, Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31(5), 578–583 (2000)CrossRef

B.A. Gartrell, F. Saad, Managing bone metastases and reducing skeletal related events in prostate cancer. Nat. Rev. Clin. Oncol. 11(6), 335–345 (2014). https://doi.org/10.1038/nrclinonc.2014.70 CrossRefPubMed

D. Ribatti, G. Mangialardi, A. Vacca, Stephen Paget and the “seed and soil” theory of metastatic dissemination. Clin. Exp. Med. 6(4), 145–149 (2006). https://doi.org/10.1007/s10238-006-0117-4 CrossRefPubMed

F. Rahim, S. Hajizamani, E. Mortaz, A. Ahmadzadeh, M. Shahjahani, S. Shahrabi, N. Saki, Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res. 2014, 405920 (2014). https://doi.org/10.1155/2014/405920 CrossRefPubMedPubMedCentral

S. D’Oronzo, J. Brown, R. Coleman, The role of biomarkers in the management of bone-homing malignancies. J. Bone Oncol. 9, 1–9 (2017). https://doi.org/10.1016/j.jbo.2017.09.001 CrossRefPubMedPubMedCentral

F. Minisola, C. Cipriani, L. Colangelo, M. Cilli, A. Sciarra, M. Von Heland, L. Nieddu, E. Anastasi, R. Pascone, V. Fassino, D. Diacinti, F. Longo, S. Minisola, J. Pepe, Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study. Endocrine 59(2), 338–343 (2018). https://doi.org/10.1007/s12020-017-1351-0 CrossRefPubMed

10.

M.W. Yeh, P.H. Ituarte, H.C. Zhou, S. Nishimoto, I.L. Liu, A. Harari, P.I. Haigh, A.L. Adams, Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J. Clin. Endocrinol. Metab. 98(3), 1122–1129 (2013). https://doi.org/10.1210/jc.2012-4022 CrossRefPubMedPubMedCentral

11.

N. Mottet, J. Bellmunt, M. Bolla, E. Briers, M.G. Cumberbatch, M. De Santis, N. Fossati, T. Gross, A.M. Henry, S. Joniau, T.B. Lam, M.D. Mason, V.B. Matveev, P.C. Moldovan, R.C.N. van den Bergh, T. Van den Broeck, H.G. van der Poel, T.H. van der Kwast, O. Rouviere, I.G. Schoots, T. Wiegel, P. Cornford, EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71(4), 618–629 (2017). https://doi.org/10.1016/j.eururo.2016.08.003 CrossRefPubMed

12.

U. Cinamon, R.E. Turcotte, Primary hyperparathyroidism and malignancy: “studies by nature”. Bone 39(2), 420–423 (2006). https://doi.org/10.1016/j.bone.2006.01.146 CrossRefPubMed

13.

M. Palmer, H.O. Adami, U.B. Krusemo, S. Ljunghall, Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am. J. Epidemiol. 127(5), 1031–1040 (1988)CrossRef

14.

A.L. Pickard, G. Gridley, L. Mellemkjae, C. Johansen, A. Kofoed-Enevoldsen, K.P. Cantor, L.A. Brinton, Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 95(8), 1611–1617 (2002). https://doi.org/10.1002/cncr.10846 CrossRefPubMed

15.

K.B. Michels, F. Xue, L. Brandt, A. Ekbom, Hyperparathyroidism and subsequent incidence of breast cancer. Int. J. Cancer 110(3), 449–451 (2004). https://doi.org/10.1002/ijc.20155 CrossRefPubMed

16.

S. Palmieri, L. Roggero, E. Cairoli, V. Morelli, A. Scillitani, I. Chiodini, C. Eller-Vainicher, Occurrence of malignant neoplasia in patients with primary hyperparathyroidism. Eur. J. Intern. Med. 43, 77–82 (2017). https://doi.org/10.1016/j.ejim.2017.06.001 CrossRefPubMed

17.

M.F. McCarty, Parathyroid hormone may be a cancer promoter—an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med. Hypotheses 54(3), 475–482 (2000). https://doi.org/10.1054/mehy.1999.0880 CrossRefPubMed

18.

S. Takahashi, M. Hakuta, K. Aiba, Y. Ito, N. Horikoshi, M. Miura, K. Hatake, E. Ogata, Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr. Relat. Cancer 10(3), 403–407 (2003)CrossRef

19.

F.C. Cackowski, R.S. Taichman, Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation. Bone (2018). 10.1016/j.bone.2018.02.025

20.

H. Huang, C. Wang, F. Liu, H.Z. Li, G. Peng, X. Gao, K.Q. Dong, H.R. Wang, D.P. Kong, M. Qu, L.H. Dai, K.J. Wang, Z. Zhou, J. Yang, Z.Y. Yang, Y.Q. Cheng, Q.Q. Tian, D. Liu, C.L. Xu, D.F. Xu, X.G. Cui, Y.H. Sun, Reciprocal network between cancer stem-like cells and macrophages facilitates the progression and androgen deprivation therapy resistance of prostate cancer. Clin. Cancer Res. (2018). 10.1158/1078-0432.Ccr-18-0461

21.

S.A. de Bessa Garcia, A.C. Pavanelli, E.M.N. Cruz, M.A. Nagai, Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity. Int. J. Mol. Med. 39(4), 809–818 (2017). https://doi.org/10.3892/ijmm.2017.2900 CrossRefPubMedPubMedCentral

22.

M.F. Leeman, S. Curran, G.I. Murray, The structure, regulation, and function of human matrix metalloproteinase-13. Crit. Rev. Biochem. Mol. Biol. 37(3), 149–166 (2002). https://doi.org/10.1080/10409230290771483 CrossRefPubMed

23.

T.M. Murray, L.G. Rao, P. Divieti, F.R. Bringhurst, Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr. Rev. 26(1), 78–113 (2005). https://doi.org/10.1210/er.2003-0024 CrossRefPubMed

24.

M. Iwamura, P.A. Abrahamsson, K.A. Foss, G. Wu, A.T. Cockett, L.J. Deftos, Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43(5), 675–679 (1994)CrossRef

25.

S. Feng, J. Wang, Y. Zhang, C.J. Creighton, M. Ittmann, FGF23 promotes prostate cancer progression. Oncotarget 6(19), 17291–17301 (2015). https://doi.org/10.18632/oncotarget.4174 CrossRefPubMedPubMedCentral

26.

L. Michaud, A. Burgess, V. Huchet, M. Lefevre, M. Tassart, J. Ohnona, K. Kerrou, S. Balogova, J.N. Talbot, S. Perie, Is ¹⁸F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J. Clin. Endocrinol. Metab. 99(12), 4531–4536 (2014). https://doi.org/10.1210/jc.2014-2821 CrossRefPubMed

27.

R. Scalco, M.O. Premaor, P.E. Fröehlich, T.W. Furlanetto, High prevalence of hypovitaminosis D and secondary hyperparathyroidism in elders living in nonprofit homes in South Brazil. Endocrine 33(1), 95–100 (2008). https://doi.org/10.1007/s12020-008-9061-2 CrossRefPubMed

28.

J.-C. Souberbielle, C. Massart, S. Brailly-Tabard, E. Cavalier, P. Chanson, Prevalence and determinants of vitamin D deficiency in healthy French adults: the VARIETE study. Endocrine 53(2), 543–550 (2016). https://doi.org/10.1007/s12020-016-0960-3 CrossRefPubMed

29.

R. Pedersini, S. Monteverdi, G. Mazziotti, V. Amoroso, E. Roca, F. Maffezzoni, L. Vassalli, F. Rodella, A.M. Formenti, S. Frara, R. Maroldi, A. Berruti, E. Simoncini, A. Giustina, Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study. Bone 97, 147–152 (2017). https://doi.org/10.1016/j.bone.2017.01.013 CrossRefPubMed

30.

G. Mazziotti, A.M. Formenti, S. Frara, R. Olivetti, G. Banfi, M. Memo, R. Maroldi, R. Giubbini, A. Giustina, High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. J. Clin. Endocrinol. Metab. 103(3), 956–964 (2018). https://doi.org/10.1210/jc.2017-01986 CrossRefPubMed

31.

G. Mazziotti, A.M. Formenti, M.B. Panarotto, E. Arvat, A. Chiti, A. Cuocolo, M.E. Dottorini, C. Durante, L. Agate, S. Filetti, F. Felicetti, A. Filice, L. Pace, T. Pellegrino, M. Rodari, M. Salvatori, C. Tranfaglia, A. Versari, D. Viola, S. Frara, A. Berruti, A. Giustina, R. Giubbini, Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine 59(1), 90–101 (2018). https://doi.org/10.1007/s12020-017-1455-6 CrossRefPubMed

32.

R. Rizzoli, J.J. Body, M.L. Brandi, J. Cannata-Andia, D. Chappard, A. El Maghraoui, C.C. Gluer, D. Kendler, N. Napoli, A. Papaioannou, D.D. Pierroz, M. Rahme, C.H. Van Poznak, T.J. de Villiers, El Hajj Fuleihan, G.: Cancer-associated bone disease. Osteoporos. Int. 24(12), 2929–2953 (2013). https://doi.org/10.1007/s00198-013-2530-3 CrossRefPubMedPubMedCentral

33.

G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123(10), 877–884 (2010). https://doi.org/10.1016/j.amjmed.2010.02.028 CrossRefPubMed

34.

G.G. Schwartz, Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 17(3), 478–483 (2008). https://doi.org/10.1158/1055-9965.Epi-07-2747 CrossRef

35.

A. Berruti, R. Cook, F. Saad, C. Buttigliero, A. Lipton, M. Tampellini, K.A. Lee, R.E. Coleman, M.R. Smith, Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 17(5), 645–652 (2012). https://doi.org/10.1634/theoncologist.2011-0448 CrossRefPubMedPubMedCentral

36.

A.A. Khan, D.A. Hanley, R. Rizzoli, J. Bollerslev, J.E. Young, L. Rejnmark, R. Thakker, P. D’Amour, T. Paul, S. Van Uum, M.Z. Shrayyef, D. Goltzman, S. Kaiser, N.E. Cusano, R. Bouillon, L. Mosekilde, A.W. Kung, S.D. Rao, S.K. Bhadada, B.L. Clarke, J. Liu, Q. Duh, E.M. Lewiecki, F. Bandeira, R. D’Amour, C. Marcocci, S.J. Silverberg, R. Udelsman, K.S. Davison, J.T. Potts Jr., M.L. Brandi, J.P. Bilezikian, Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int. 28(1), 1–19 (2017). https://doi.org/10.1007/s00198-016-3716-2 CrossRefPubMed

Title: Primary hyperparathyroidism in prostate cancer: guilty or not guilty?
Authors: G. Mazziotti
S. Frara
A. Mosca
Publication date: 01-11-2018
Publisher: Springer US
Published in: Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1632-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Primary hyperparathyroidism in prostate cancer: guilty or not guilty?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2018

Strategies to reduce readmissions for hyponatremia after transsphenoidal surgery for pituitary adenomas

Insights on the phenotypic heterogenity of 11β-hydroxylase deficiency: clinical and genetic studies in two novel families

Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis

LncRNAs and miRs as epigenetic signatures in diabetic cardiac fibrosis: new advances and perspectives

Water intake keeps type 2 diabetes away? Focus on copeptin

New modified Friedewald formulae for estimating low-density lipoprotein cholesterol according to triglyceride levels: extraction and validation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page